JUN dependency in distinct early and late BRAF inhibition adaptation states of melanoma

Systematic analysis of BRAFV600E melanomas reveals a role for JNK/c-Jun pathway in adaptive resistance to drug-induced apoptosis

(2015) M. Fallahi-Sichani et al.   Molecular Systems Biology

The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma

(2015) Rachel Ramsdale et al.   Science Signaling

The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma

(2015) Rachel Ramsdale et al.   Science Signaling

Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers

(2015) Ryan B. Corcoran et al.   Oncotarget

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma

(2014) Chong Sun et al.   NATURE

Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma

(2014) Judith Müller et al.   Nature Communications

A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors

(2014) D. J. Konieczkowski et al.   Cancer Discovery

Ligand-Independent EPHA2 Signaling Drives the Adoption of a Targeted Therapy-Mediated Metastatic Melanoma Phenotype

(2014) K. H. T. Paraiso et al.   Cancer Discovery

Overcoming Intrinsic Multidrug Resistance in Melanoma by Blocking the Mitochondrial Respiratory Chain of Slow-Cycling JARID1Bhigh Cells

(2013) Alexander Roesch et al.   CANCER CELL

A melanocyte lineage program confers resistance to MAP kinase pathway inhibition

(2013) Cory M. Johannessen et al.   NATURE

Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy

(2013) H. Shi et al.   Cancer Discovery

GFOLD: a generalized fold change for ranking differentially expressed genes from RNA-seq data

(2012) Jianxing Feng et al.   BIOINFORMATICS

Discovery of Potent and Selective Covalent Inhibitors of JNK

(2012) Tinghu Zhang et al.   CHEMISTRY & BIOLOGY

The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition

(2012) X. Jiang et al.   CLINICAL CANCER RESEARCH

Distinct functions of JNK and c-Jun in oxidant-induced hepatocyte death

(2012) Muhammad Amir et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Frequency and Spectrum of BRAF Mutations in a Retrospective, Single-Institution Study of 1112 Cases of Melanoma

(2012) Wesley O. Greaves et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial

(2012) Gerald S Falchook et al.   LANCET

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

(2012) Axel Hauschild et al.   LANCET

Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation

(2012) Jennifer Landsberg et al.   NATURE

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

(2012) Ravid Straussman et al.   NATURE

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

(2012) Timothy R. Wilson et al.   NATURE

Mutations in UVSSA cause UV-sensitive syndrome and destabilize ERCC6 in transcription-coupled DNA repair

(2012) Xue Zhang et al.   NATURE GENETICS

Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

(2012) Jeffrey A. Sosman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mechanisms of intrinsic and acquired resistance to kinase-targeted therapies

(2012) Shubha Bagrodia et al.   Pigment Cell & Melanoma Research

A Multi-Cancer Mesenchymal Transition Gene Expression Signature Is Associated with Prolonged Time to Recurrence in Glioblastoma

(2012) Wei-Yi Cheng et al.   PLoS One

Cancer stem cells and epithelial–mesenchymal transition: Concepts and molecular links

(2012) Christina Scheel et al.   SEMINARS IN CANCER BIOLOGY

Melanoma whole-exome sequencing identifies V600E B-RAF amplification-mediated acquired B-RAF inhibitor resistance

(2012) Hubing Shi et al.   Nature Communications

Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma

(2012) Maria R. Girotti et al.   Cancer Discovery

Mutant BRAF Melanomas—Dependence and Resistance

(2011) Poulikos I. Poulikakos et al.   CANCER CELL

Human CD271-Positive Melanoma Stem Cells Associated with Metastasis Establish Tumor Heterogeneity and Long-term Growth

(2011) G. Civenni et al.   CANCER RESEARCH

ETS-1/RhoC signaling regulates the transcription factor c-Jun in melanoma

(2011) Barbara Spangler et al.   INTERNATIONAL JOURNAL OF CANCER

Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling

(2011) Nikhil Wagle et al.   JOURNAL OF CLINICAL ONCOLOGY

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

(2011) Poulikos I. Poulikakos et al.   NATURE

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adaptive upregulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells

(2011) K J Basile et al.   ONCOGENE

Global Phosphoproteomics Reveals Crosstalk Between Bcr-Abl and Negative Feedback Mechanisms Controlling Src Signaling

(2011) L. Rubbi et al.   Science Signaling

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

(2011) L. V. Sequist et al.   Science Translational Medicine

Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K

(2010) Jessie Villanueva et al.   CANCER CELL

Jun Proteins Are Starvation-Regulated Inhibitors of Autophagy

(2010) O. Yogev et al.   CANCER RESEARCH

FOXD3 Is a Mutant B-RAF–Regulated Inhibitor of G1-S Progression in Melanoma Cells

(2010) Ethan V. Abel et al.   CANCER RESEARCH

Targeting Multiple Kinase Pathways: A Change In Paradigm

(2010) L. Gossage et al.   CLINICAL CANCER RESEARCH

Activation of Aortic Endothelial Cells by Oxidized Phospholipids: A Phosphoproteomic Analysis

(2010) Alejandro Zimman et al.   JOURNAL OF PROTEOME RESEARCH

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

(2010) Ramin Nazarian et al.   NATURE

Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271

(2010) Alexander D. Boiko et al.   NATURE

A global map of human gene expression

(2010) Margus Lukk et al.   NATURE BIOTECHNOLOGY

CCancer: a bird's eye view on gene lists reported in cancer-related studies

(2010) S. Dietmann et al.   NUCLEIC ACIDS RESEARCH

Rank–rank hypergeometric overlap: identification of statistically significant overlap between gene-expression signatures

(2010) Seema B. Plaisier et al.   NUCLEIC ACIDS RESEARCH

The proximal signaling network of the BCR-ABL1 oncogene shows a modular organization

(2010) B Titz et al.   ONCOGENE

EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer

(2010) A Singh et al.   ONCOGENE

Melanoma stem cells - are there devils in the detail?

(2010) Mark Shackleton   Pigment Cell & Melanoma Research

Cancer stem cells versus phenotype-switching in melanoma

(2010) Keith S. Hoek et al.   Pigment Cell & Melanoma Research

Post-transcriptional regulation controlled by E-cadherin is important for c-Jun activity in melanoma

(2010) B. Spangler et al.   Pigment Cell & Melanoma Research

A proliferative melanoma cell phenotype is responsive to RAF/MEK inhibition independent of BRAF mutation status

(2010) Marie C. Zipser et al.   Pigment Cell & Melanoma Research

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner

(2010) E. W. Joseph et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

TGF-  IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer

(2010) Z. Yao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Epithelial-Mesenchymal Transition-Derived Cells Exhibit Multilineage Differentiation Potential Similar to Mesenchymal Stem Cells

(2010) Venkata Lokesh Battula et al.   STEM CELLS

A human functional protein interaction network and its application to cancer data analysis

(2010) Guanming Wu et al.   GENOME BIOLOGY

Epithelial-Mesenchymal Transitions in Development and Disease

(2009) Jean Paul Thiery et al.   CELL

c-Jun Regulates Phosphoinositide-dependent Kinase 1 Transcription

(2009) Pablo Lopez-Bergami et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The basics of epithelial-mesenchymal transition

(2009) Raghu Kalluri et al.   JOURNAL OF CLINICAL INVESTIGATION

Universal sample preparation method for proteome analysis

(2009) Jacek R Wiśniewski et al.   NATURE METHODS

Epithelial-to-Mesenchymal Transition and Integrin-Linked Kinase Mediate Sensitivity to Epidermal Growth Factor Receptor Inhibition in Human Hepatoma Cells

(2008) B. C. Fuchs et al.   CANCER RESEARCH

In vivo Switching of Human Melanoma Cells between Proliferative and Invasive States

(2008) K. S. Hoek et al.   CANCER RESEARCH

Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions

(2008) Sharon Barr et al.   CLINICAL & EXPERIMENTAL METASTASIS

Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy

(2008) Stuart Thomson et al.   CLINICAL & EXPERIMENTAL METASTASIS

Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials

(2008) Edward L. Korn et al.   JOURNAL OF CLINICAL ONCOLOGY

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

(2008) J. Tsai et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A review of the S100 proteins in cancer

(2007) I. Salama et al.   EJSO